Compare Abbott Laboratories (ABT) vs Teucrium Wheat Fund (WEAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Teucrium Wheat Fund — how do they compare? Abbott Laboratories trades at $109.01 (market cap $187.95B), while Teucrium Wheat Fund trades at $24.01. The key difference: Abbott Laboratories pays a 2.32% dividend while Teucrium Wheat Fund pays none, and Teucrium Wheat Fund is trading nearer its 52-week high, Abbott Laboratories nearer its low. Which is the better fit depends on your goals.
| ABT | WEAT | |
|---|---|---|
Market Cap | $187.95B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $136.62 | $26.00 |
52-Week Low | $82.57 | $19.88 |
Enterprise Value | $214.96B | — |
Dividend Yield | 2.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $109.74, up 1.8% on the day, with a bullish technical signal from moving averages and strong analyst consensus. Recent financials show revenue growth to $44.33 billion in 2025, though net income declined to $6.52 billion. Key developments include a CE Mark for dual glucose-ketone sensors, enhancing its diabetes care portfolio. The stock is near its 52-week high, with support at $108 and resistance at $109.
Outlook remains positive with a consensus price target of $120.70, offering ~10% upside. Risks include competitive pressures in medical devices and macroeconomic volatility. Earnings beats in Q1 and Q2 2026 support growth, but margin compression and high P/E of 35.15 warrant caution for value-focused investors.
WEAT, the Teucrium Wheat Fund, trades at $23.91, up 0.8% on the day, with a neutral technical signal overall. Recent performance shows strength, gaining 9.9% over the past month and 25% year-to-date as of July 21, 2026 (Zacks Investment Research). Key support and resistance cluster around $24, while oscillators like the relative strength index indicate neutral momentum. The USDA's reduced wheat production outlook for 2026 to 1.56 billion bushels, below analyst expectations (WSJ, May 12, 2026), underscores supply-side influences.
Outlook remains tied to agricultural commodity cycles; inflation trends and crop forecasts drive volatility. Risks include weather disruptions and global demand shifts, but current sentiment is balanced with potential for further gains if supply constraints persist.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Teucrium Wheat Fund
WEAT is a commodity ETF that provides exposure to the price of wheat futures. It employs a laddered strategy across multiple benchmark contracts to mitigate the effects of contango and roll costs inherent in agricultural futures trading.
Read more on WEAT →
